Adding Liraglutide to High Dose Insulin: Breaking the Cycle
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a
high-dose insulin regimen (>1.8 units/kg/day) in patients with uncontrolled (HbA1c >7.5%)
type 2 diabetes mellitus will improve blood sugar control.
It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the
mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and
assesses blood pressure, lipid profile, and liver function. Finally it will look at patient
quality of life and safety.